Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
—
—
—
Novartis India Limited manufactures drugs, medicines and allied products. The Company is engaged in the wholesale of pharmaceuticals and medical goods.
Customise key metrics, see detailed forecasts, download stock data and more
Pledged promoter holdings is insignificant
In last 3 months, mutual fund holding of the company has almost stayed constant
NOVARTIS INDIA LTD. - 500672 - Board Meeting Intimation for Board Meeting Intimation For The Consideration And Approval Of Unaudited Financial Results For The Quarter Ended September 30, 2024. | Download
NOVARTIS INDIA LTD. - 500672 - Board Meeting Intimation for Board Meeting Intimation For The Consideration And Approval Of Unaudited Financial Results For The Quarter Ended September 30, 2024. | Download
Final • Div/Share: ₹ 25
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant